Santoso S, Kunicki T
Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig University Giessen, Germany.
Ital Heart J. 2001 Nov;2(11):811-5.
Plaque rupture and/or endothelial damage lead to exposure of von Willebrand factor and collagen which facilitate the adhesion of circulating platelets via glycoprotein Ib-IX-V and the integrin alpha2 beta1, respectively, to the damaged vessel wall. This process activates the platelet and leads to a conformational change of a second integrin alphaIIb beta3 that facilitates fibrinogen binding and platelet aggregation. Thrombin generated at the blood-plaque interface converts fibrinogen to fibrin, which stabilizes thrombus growth. Therefore, any genetic differences that might alter surface expression or activity of these receptors could influence risk for adverse outcomes as a result of the haemostatic process. In the last 5 years, there has been a rapid accumulation of the literature concerning the relationship between genetic variations in platelet glycoproteins and risk for coronary heart disease. In this chapter, we present a comprehensive review of the impact of platelet receptor polymorphisms and thrombotic risk.
斑块破裂和/或内皮损伤导致血管性血友病因子和胶原蛋白暴露,这分别通过糖蛋白Ib-IX-V和整合素α2β1促进循环血小板与受损血管壁的黏附。这一过程激活血小板,并导致第二种整合素αIIbβ3发生构象变化,从而促进纤维蛋白原结合和血小板聚集。在血液-斑块界面产生的凝血酶将纤维蛋白原转化为纤维蛋白,从而稳定血栓生长。因此,任何可能改变这些受体表面表达或活性的基因差异都可能影响止血过程导致不良后果的风险。在过去5年里,关于血小板糖蛋白基因变异与冠心病风险之间关系的文献迅速积累。在本章中,我们全面综述血小板受体多态性的影响和血栓形成风险。